Browse Category

NASDAQ:HQY 9 January 2026 - 12 January 2026

HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

HealthEquity shares fell about 10% Monday after the company issued a cautious initial fiscal 2027 outlook, projecting revenue between $1.38 billion and $1.41 billion and an HSA cash yield near 3.75%. The stock last traded at $84.62, down $9.53. Executives will present at the J.P. Morgan Healthcare Conference on Tuesday. The company reaffirmed its 2026 guidance.
HealthEquity stock slides after Goldman Sachs downgrade; HQY earnings watch shifts to March

HealthEquity stock slides after Goldman Sachs downgrade; HQY earnings watch shifts to March

HealthEquity shares dropped 2.9% to $95.64 Friday after Goldman Sachs downgraded the stock to sell and set an $89 target. The move followed HealthEquity’s raised fiscal 2026 revenue outlook and a report of $34.4 billion in HSA assets. KeyBanc maintained an Overweight rating and lifted its price target to $125. The stock fell as the S&P 500 and Nasdaq 100 rose.
Go toTop